JP5503837B2 - 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 - Google Patents

非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 Download PDF

Info

Publication number
JP5503837B2
JP5503837B2 JP2006509376A JP2006509376A JP5503837B2 JP 5503837 B2 JP5503837 B2 JP 5503837B2 JP 2006509376 A JP2006509376 A JP 2006509376A JP 2006509376 A JP2006509376 A JP 2006509376A JP 5503837 B2 JP5503837 B2 JP 5503837B2
Authority
JP
Japan
Prior art keywords
cal
group
vip
covalent
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006509376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527373A (ja
Inventor
ポール，サッドヒル
泰弘 西山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2007527373A publication Critical patent/JP2007527373A/ja
Application granted granted Critical
Publication of JP5503837B2 publication Critical patent/JP5503837B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2006509376A 2003-03-26 2004-03-26 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合 Expired - Fee Related JP5503837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45729303P 2003-03-26 2003-03-26
US60/457,293 2003-03-26
PCT/US2004/009399 WO2004087059A2 (en) 2003-03-26 2004-03-26 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010265465A Division JP5827003B2 (ja) 2003-03-26 2010-11-29 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合

Publications (2)

Publication Number Publication Date
JP2007527373A JP2007527373A (ja) 2007-09-27
JP5503837B2 true JP5503837B2 (ja) 2014-05-28

Family

ID=33131674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006509376A Expired - Fee Related JP5503837B2 (ja) 2003-03-26 2004-03-26 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
JP2010265465A Expired - Fee Related JP5827003B2 (ja) 2003-03-26 2010-11-29 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010265465A Expired - Fee Related JP5827003B2 (ja) 2003-03-26 2010-11-29 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合

Country Status (5)

Country Link
US (1) US9006388B2 (enExample)
EP (1) EP1610808A4 (enExample)
JP (2) JP5503837B2 (enExample)
CA (1) CA2520392C (enExample)
WO (1) WO2004087059A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980646B2 (en) 2003-03-26 2015-03-17 Sudhir Paul Proteolytic and covalent antibodies
JP5503837B2 (ja) * 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
WO2004087738A2 (en) 2003-03-27 2004-10-14 The University Of Texas Lupus antibodies for passive immunotherapy of hiv/aids
BRPI0813948B8 (pt) * 2007-07-10 2021-05-25 Medy Tox Inc composição líquida farmacêutica de toxina botulínica com estabilidade melhorada
CN105574346A (zh) * 2008-09-05 2016-05-11 新基阿维罗米克斯研究公司 多肽偶联物与不可逆抑制剂的设计方法和检测方法
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
EP3511424B1 (en) 2012-08-03 2023-10-18 University Of Washington Through Its Center For Commercialization Compositions and methods for improving nanopore sequencing
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952462A (en) 1983-11-29 1999-09-14 Igen International Inc. Transition state analogs
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5801149A (en) * 1991-06-19 1998-09-01 Joslin D-Abetes Center, Inc. Inhibition of signal transduction molecules
WO1993015751A1 (en) * 1992-02-14 1993-08-19 Merck & Co., Inc. CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5952307A (en) * 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5916877A (en) * 1994-10-18 1999-06-29 Georgia Tech Research Corporation Fluorescent 1-peptidylaminoalkanephosphonate derivatives
CN1165344C (zh) 1995-07-21 2004-09-08 内布拉斯卡大学评议会 用于催化水解HIVgp120的组合物及其制备方法和用途
US6855804B2 (en) 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
US6235714B1 (en) * 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
EP1085880A2 (en) * 1998-06-11 2001-03-28 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
WO2002079223A2 (en) * 2001-03-31 2002-10-10 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
JP5503837B2 (ja) * 2003-03-26 2014-05-28 ポール，サッドヒル 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
US8980646B2 (en) 2003-03-26 2015-03-17 Sudhir Paul Proteolytic and covalent antibodies
WO2004087738A2 (en) 2003-03-27 2004-10-14 The University Of Texas Lupus antibodies for passive immunotherapy of hiv/aids
EP2091973A4 (en) * 2006-11-09 2010-08-04 Sudhir Paul ANTIBODIES TO BINARY EPITOPES AND B-CELL SUPERANTIGEN IMMUNOSTIMULANTS
US9969797B2 (en) * 2008-04-23 2018-05-15 Covalent Bioscience Incorporated Immunoglobulins directed to bacterial, viral and endogenous polypeptides
US20120121633A1 (en) * 2010-07-16 2012-05-17 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions

Also Published As

Publication number Publication date
CA2520392A1 (en) 2004-10-14
WO2004087059A3 (en) 2005-07-21
JP2007527373A (ja) 2007-09-27
CA2520392C (en) 2014-08-12
US9006388B2 (en) 2015-04-14
EP1610808A2 (en) 2006-01-04
US20070179083A1 (en) 2007-08-02
WO2004087059A2 (en) 2004-10-14
JP5827003B2 (ja) 2015-12-02
JP2011105724A (ja) 2011-06-02
EP1610808A4 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
JP5827003B2 (ja) 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
Díaz-Salinas et al. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
Uppalapati et al. A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo
JP2931609B2 (ja) 触媒抗体を使用する治療方法
JP4939929B2 (ja) タンパク質分解抗体および共有結合抗体
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
JP3872813B2 (ja) ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
TW202014436A (zh) 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
JP2002507627A (ja) 蛋白分解性抗体のインデューサーおよび阻害剤を同定する方法、組成物ならびにそれらの使用
WO2021198999A1 (en) Epitope-based vaccines for treatment of coronavirus associated diseases
Laustsen et al. In vivo neutralization of myotoxin II, a phospholipase A2 homologue from Bothrops asper venom, using peptides discovered via phage display technology
Bar et al. Determination of the rituximab binding site to the CD20 epitope using SPOT synthesis and surface plasmon resonance analyses
Capini et al. Active immunization against murine TNFα peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection
US12350322B2 (en) Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation
ES2212801T3 (es) Peptidos sinteticos y composiciones farmaceuticas que los contienen para el tratamiento del lupus eritematoso sistemico.
Chan et al. Tuning the anti-angiogenic effect of the P15 peptide using cyclic trypsin inhibitor scaffolds
US20100104580A1 (en) Altered Immunogenic Landscape in HIV-1 Envelope Proteins
EP4624487A1 (en) Production of antibodies against protein
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
JPH10182696A (ja) ｇｐ１２０に対して親和性を有するペプチド
CN107849119A (zh) 用于治疗和预防IgE介导的疾病的疫苗
JP3780421B2 (ja) ヒト免疫不全ウイルスに対するワクチンおよびその製造方法
JP2023542389A (ja) 自己抗体で媒介される状態の予防又は治療のための化合物
Diaz-Salinas et al. eScholarship@ UMassChan
EP3658581A1 (en) Antibodies and peptides to treat hcmv related diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070815

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101215

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140317

R150 Certificate of patent or registration of utility model

Ref document number: 5503837

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees